Podcasts about CNS

Unlike the adjuvant space, treatment of advanced clear cell renal cell cancer has been a success story potentially only surpassed by advanced melanoma. What was once a horrific and quickly fatal disease, with a predilection for the CNS and significant bleeding risk has become significantly less so. In this episode, Josh and Michael explore the studies that have made it happen.Studies discussed in this episodeCLEARCheckmate 214Checkmate 9ERFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

In this episode, The First Lady of Nutrition welcomes Dr. Noel Baker, a respected functional medicine practitioner and one of the foremost protégés of Dr. Theodore Baroody, author of the groundbreaking book, The Hiatal Hernia Syndrome: The Mother of All Illnesses. Together, they explore a little-understood health issue—a hiatal hernia, which is essentially a misalignment of the stomach that can trigger a ripple effect of symptoms throughout the body. Ann Louise speaks from experience, having personally worked with Dr. Baker and experienced the healing process firsthand. A hiatal hernia is more than just a mechanical issue or a cause of common indigestion. It can be the hidden source behind a wide array of symptoms that many people—and their doctors—struggle to explain. This can include alarming symptoms that mimic heart attacks, a hijacked fight-or-flight response, disrupted vagus nerve function, trouble taking a deep breath and swallowing, plus a domino effect of stress-related imbalances throughout the body including anxiety. Listeners will also gain insight into the importance of the “alpha state,” the role of neurofeedback in restoring calm and nervous system balance, and how holistic practices like grounding, yoga, stretching—and even an unconventional method known as the “stomach egg”—can play a powerful role in the healing process. To connect with Dr. Noel Baker and his team, visit PureFunctionalMedicine.com. The post Hiatal Hernia: The Mother of All Illnesses – Episode 200: Dr. Noel Baker first appeared on Ann Louise Gittleman, PhD, CNS.

What is the role of a Clinical Nurse Specialist (CNS) in the ICU? How did Lynette LaBine, MSN, RN, CNS, CCRN leverage her CNS role to win buy-in and guide her team to become an Awake and Walking ICU? Lynette shares with us how consulting and training services opened the doors for her to fully lead the revolution in her ICU. Listen and watch Lynette's RN colleagues HERE and rehab colleagues HERE! Get your CE credit for this episode and all learning you do here!Want to bring the revolution to your ICU? Check out www.DaytonICUConsulting.com

L-Glutamine stands as one of the most powerful amino acids for optimizing gut health, muscle function, immune and brain health. It's a common solution for leaky gut, but overall can enhance the improvement of other therapies. In this episode, I'll dive into the benefits of l-glutamine, the best food sources, and effective protocols for different conditions.    ✅ Start healing with us! Learn more about our virtual clinic:https://drruscio.com/virtual-clinic/

In this episode of The Sunday BBQ, Kevin Hornsby is joined by Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS), to discuss the Company's latest progress across its mental health and addiction treatment pipeline. Anthony outlines the £1 million investment from key shareholders to accelerate Solvonis' AI-driven CNS drug discovery programme, as well as the initiation of pivotal translational studies for SVN‑002 — a novel treatment for Alcohol Use Disorder — ahead of a Phase 2b trial in the US. We also explore the company's strategic use of the FDA's 505(b)(2) pathway and why its differentiated pipeline continues to attract attention in the neuropsychiatry space. Disclaimer & Declaration of Interest This podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast. 

For a captioned version or to access the transcript, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-14-cns-modelling/In this podcast, Scott Summerfield and Professor Elizabeth de Lange discuss the evolution of CNS drug disposition models, highlighting the increasing sophistication of physiologically based pharmacokinetic (PBPK) models, such as LeiCNS-PK3.0. They discuss how these tools are enhancing our understanding of CNS drug distribution, predicting human pharmacokinetics, and supporting translational research across species.We will address the following questions:What scientific needs led to the development of early CNS drug models?How have tools like microdialysis and PBPK modeling shaped current CNS pharmacokinetic models?What role does the unbound drug concentration (Kpuu) play in predicting CNS drug effects?How do modern models like LeiCNS-PK3.0 integrate complex physiological and pharmacodynamic data?What are the future research directions and translational opportunities in CNS PK/PD modeling?Our Moderator:Scott Summerfield – Executive Director Metabolism at PharmaronScott Summerfield is the head of Metabolism, leading clinical and nonclinical radiolabeled ADME (Pharma and Environmental), in vivo support, imaging, as well as Discovery/Development and bioanalysis metabolite ID. Scott joined Pharmaron in 2022, having worked in the Pharmaceutical Industry for over 20 years, supporting both small and large molecule DMPK projects (Discovery and Development). He holds a PhD and a postdoctoral degree in protein mass spectrometry. He has published extensively in the areas of bioanalysis and the permeation of drugs across the blood-brain barrier.Our Speaker:Elizabeth de Lange – Professor Predictive Pharmacology at Leiden UniversityElizabeth de Lange is a Professor in Predictive Pharmacology and Principal Investigator at the Research Division of Systems Pharmacology and Pharmacy of the Leiden Academic Center for Drug Research (LACDR). With her team, she is helping to unravel the rate and extent of mechanisms that govern central nervous system (CNS) target site pharmacokinetics (PK) and related pharmacodynamics (PD), with a special emphasis on physiologically based (PB) translation between species and conditions. The ultimate aim is to have mathematical models that support CNS drug development (including reduction and replacement of nonclinical studies) and can predict the best possible treatment for CNS conditions in the individual patient (‘tailor-made'). Elizabeth has contributed over 160 peer-reviewed publications, delivered more than 170 invited lectures, and organized numerous conferences, symposia, courses, and workshops. She has had multiple leadership positions in scientific projects, also at LACDR, nationally with the NVF, in large international organizations (e.g., AAPS), and is currently the scientific coordinator of the EU consortium QSPainRelief. She has several roles on advisory board, provides both advice and consultancy, and alongside all of this Elizabeth contributes to education in the BioPharmaceutical Sciences bachelor's and master courses. Among other honors, Elizabeth received the AAPS Fellow Award (2013), an Honorary Doctorate in Pharmacy from Uppsala University (2020), and the prestigious Sheiner Lecture Lifetime Achievement Award from ISOP (2020).Stay tuned for more podcasts in our Pharmaron DMPK Insights Series!

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain, practicing community oncologists, share their key takeaways from a session on NTRK Fusion Positive Solid Malignancies, they moderated during a satellite event at ASCO 2025 in partnership with Medscape Global Oncology. Join us as we discuss: •⁠  ⁠The prevalence of NTRK fusions in various cancers and why community oncologists should be aware of them. •⁠  ⁠The importance of comprehensive next-generation sequencing (NGS) for detecting these fusions across diverse histologies. •⁠  ⁠Available treatment options, including first-generation NTRK inhibitors like larotrectinib and entrectinib, and their efficacy in improving overall and progression-free survival. •⁠  ⁠Insights into the CNS activity of these treatments and the common side effects patients may experience. •⁠  ⁠Special considerations for pediatric patients, including formulation challenges and the potential for re-challenging with NTRK inhibitors. Don't forget to check out the full accredited enduring program by Medscape Global Oncology linked below, and earn your CME credit.  https://www.medscape.org/viewarticle/1002679?src=acdmpart_onc-brothers_1002679  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ #entrectinib #larotrectinib #repotrectinib

On episode 523 of The Nurse Keith Show nursing and healthcare career podcast, Keith interviews author, nursing educator, and researcher Dr. Ruth Wittmann-Price, PhD, RN, CNS, CNE, CNEcl, CHSE, ANEF, FAAN. In the course of their conversation, Keith and Dr. Wittmann-Price discuss the importance and impact of competency-based education in nursing. Dr. Wittmann-Price also reflects on her storied career, and her perceptions and experiences as a highly accomplished nurse academician and writer. Ruth A. Wittmann-Price, PhD, RN, CNS, CNE, CNEcl, CHSE, ANEF, FAAN, is Dean of the W. Cary Edwards School of Nursing and Health Professionals at Thomas Edison State University in Trenton, NJ. Ruth has been an obstetrical/women's health nurse for 47 years. Dr. Wittmann-Price received her AAS and BSN degrees from Felician College, Lodi, New Jersey, and her MS as a perinatal clinical nurse specialist (CNS) from Columbia University, New York, New York. She completed her PhD in nursing at Widener University, Chester, Pennsylvania, and received the Dean's Award for Excellence. Ruth developed a mid-range nursing theory, “Emancipated Decision-Making in Women's Health Care,” and has tested her theory in four research studies. International researchers are currently using her theory as the foundation for their studies. Her theory is being used by researchers at the University of Limpopo, South Africa, in their campaign, “Finding Solutions for Africa,” which helps women and children. Dr. Wittmann-Price has taught all levels of nursing students over the past 30 years and has completed international service-learning trips. She has coedited or authored 16 books, contributed many chapters, and written numerous articles. She has presented her research regionally, nationally, and internationally. Dr. Wittmann-Price was inducted into the National League for Nursing Academy of Nurse Educator Fellows in 2013 and became a fellow in the American Academy of Nursing in October 2015. This episode of the Nurse Keith Show is brought to you in collaboration with Springer Publishing, who have been delivering award-winning healthcare education and exam prep materials focused on nursing, behavioral health, and the health sciences for more than 70 years. We thank Springer Publishing for their support. Links: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Fast Facts About Competency-Based Education in Nursing: How to Teach Competency Mastery Certified Nurse Educator Review, 4th Edition Springer Publishing Contact Nurse Keith about holistic career coaching to elevate your nursing and healthcare career at ⁠⁠⁠⁠⁠⁠⁠NurseKeith.com⁠⁠⁠⁠⁠⁠⁠. Keith also offers services as a motivational and keynote speaker and freelance nurse writer. You can always find Keith on⁠⁠⁠⁠⁠⁠⁠ LinkedIn⁠⁠⁠⁠⁠⁠⁠. Are you looking for a novel way to empower your career and move forward in life? Keith's wife, Shada McKenzie, is a gifted astrologer and reader of the tarot who combines ancient and modern techniques to provide valuable insights into your motivations, aspirations, and life trajectory, and she offers listeners of The Nurse Keith Show a 10% discount on their first consultation. Contact Shada at ⁠⁠⁠⁠⁠⁠⁠TheCircelandtheDot.com ⁠⁠⁠⁠⁠⁠⁠or shada@thecircleandthedot.com.

Program notes:0:40 Human Phenotype project1:43 Metabolomics2:42 25 year follow up3:43 Two control groups4:00 CBT via telehealth or online5:00 2000 people with chronic pain6:00 Completion rate for videos lower6:50 RNA analysis in cancer molecular diagnostics7:50 4.8% failure rate8:50 CNS or blood cancers primarily9:25 Middle age exposure to air pollution and later cognition10:25 Poorer processing speed earlier in life11:58 End

In this episode, we are joined by Bryce Mooney and Dr. Sam Attanasio. Bryce (@brycemooneygolf) and Sam (@drsamattanasio) are co-founders of Speed Toad @speedtoad.---Follow us: Twitter - @TournamentCode Instagram - @thetournamentcode YouTube - The Tournament Code Hosted by: Cooper Collins (@coopercollins99), Jack Bergstrom (@Jack_Bergstrom), Daniel Hamrin (@DanielHamrin)Sponsored by: https://puttviewbooks.com/---(01:30) - PuttView Books opening tee shot(02:30) - background of Speed Toad(07:18) - real effects of Speed Toad(14:09) - comparison of speed implements(19:20) - strong vs. fast(26:12) - working out and swinging fast(35:14) - overspeed training(40:13) - how they got into long drive(50:01) - measuring CNS status

Asenapine is an atypical antipsychotic that acts as an antagonist at multiple receptors, including dopamine D2 and serotonin 5-HT2A, contributing to its antipsychotic and mood-stabilizing effects. Adverse effects of asenapine include somnolence, dizziness, and extrapyramidal symptoms. Because asenapine is significantly metabolized by CYP1A2, inhibitors or inducers of these enzymes can affect its plasma concentrations. Co-administration with other CNS depressants may increase the risk of sedation and impaired cognitive or motor function. Asenapine can prolong the QT interval, so caution is advised when used with other medications that affect cardiac conduction.

The First Lady of Nutrition spotlights environmental toxins expert Lara Adler. Adler is a globally recognized Environmental Health Educator who has trained thousands of practitioners to identify and address hidden toxic exposures impacting chronic health. Together, Ann Louise and Lara explore the unexpected ways chemicals in our everyday environment are sabotaging our health—and our waistlines. From hidden toxins in cookware, food packaging, and personal care products to unexpected offenders like candles, perfumes, and even your mattress, no topic is off-limits. You'll learn why the kitchen is frequently a chemical hotspot in the home, how “obesogens” may be fueling weight gain without you even consuming extra calories, and what to watch for in your bedroom, bathroom, and beyond. They even dive into the potential risks of candles, incense, tattoos, and whether essential oils are truly safe. Most importantly, Lara shares practical, doable swaps to reduce your toxic load without turning your life upside down.  Visit laraadler.com to learn more. The post How Common Household Chemicals are Disrupting Hormones, Weight & Wellbeing – Episode 199: Lara Adler first appeared on Ann Louise Gittleman, PhD, CNS.

In this episode, Sam Ashoo, MD and T.R. Eckler, MD discuss the July 2025 Emergency Medicine Practice article, Emergency Department Management of Status Epilepticus in Pediatric PatientsIntroductionWelcome and brief overview of the episodePromotion of EB Medicine's $1 for 7-day trial offerWhy Pediatric Status Epilepticus MattersSeizures make up ~1% of ED visits and ~3% of EMS callsHigh-risk and high-stakes condition requiring rapid actionStatus epilepticus now defined as ≥5 minutes of seizure activityILAE's T1 and T2 timelines help define when to treat and when damage beginsCommon CausesTop contributors:Fever/infectionStructural CNS abnormalitiesToxic ingestionsGenetic/metabolic disordersAdditional factors by age:Infants: febrile seizures, chromosomal issues, traumaSchool-age: autoimmune disordersAdolescents: eclampsia, hypertension, functional disordersAlways consider non-accidental traumaPrehospital CareIM midazolam is effective and recommended (RAMPART trial)Other options: intranasal, rectal, or IV benzodiazepinesEarly benzodiazepine administration improves outcomesImportance of airway support, glucose check, and EMS flexibilityParent-administered home meds (e.g. rectal diazepam) can be helpfulED Evaluation and Initial ManagementPrioritize ABCs: Airway, Breathing, Circulation, ConsciousnessUse end-tidal CO₂ to monitor ventilation if availablePoint-of-care glucose is essentialLabs: CMP, Mg, Phos, lactate, drug levels, pregnancy test (when indicated)Imaging: Head CT if concern for trauma, shunt malfunction, or focal signsCase examples highlight pitfalls and diagnostic delaysFirst-Line TreatmentBenzodiazepines remain the cornerstoneLorazepam preferred IV agent (0.1 mg/kg)Midazolam preferred if no IV access (IN, IM, or IO)Diazepam is also effective, especially rectallyBe mindful of respiratory depression and the need for airway controlSecond- and Third-Line TherapiesBased on ESETT trial:Levetiracetam, fosphenytoin, and valproate have similar efficacyLevetiracetam favored for safety and ease of useFosphenytoin may be avoided in trauma or toxicityValproate not recommended in mitochondrial diseasePhenobarbital reserved for refractory cases onlyRefractory Status EpilepticusDefinition: persistent seizures despite first- and second-line agentsRequires sedation and likely intubationInfusion options:Midazolam (preferred for flexibility)Propofol (short-term use only due to risk of infusion syndrome)Pentobarbital (rare, ICU-level care)Need for continuous EEG to assess seizure activitySpecial ScenariosNeonates:Watch for subtle signs (lip smacking, bicycling, tongue thrusting)Broad differential includes asphyxia, infection, metabolic errorsFebrile Status Epilepticus:Higher risk of CNS infections, especially if unvaccinatedConsider lumbar puncture if indicatedElectrolyte/Metabolic Triggers:Treat hypoglycemia, hyponatremia, and hypocalcemia directlyUse 3% saline or dextrose as appropriateDisposition and Discharge ConsiderationsMany children will require ICU-level careSome known epilepsy patients may go home if back to baselineEnsure rescue medications are up to date (rectal/intranasal benzos)Consider “clonazepam bridge” for short-term seizure preventionCollaborate with neurology for medication adjustment and follow-upFinal ThoughtsKeep treatment tables and dosing references accessibleEarly, aggressive treatment can prevent long-term harmEpisode closes with gratitude to article authors and a reminder to visit EBMedicine.netEmergency Medicine Residents, get your free subscription by writing resident@ebmedicine.net

Dr. Pallawi Torka of Memorial Sloan Kettering Cancer Center joins to share highlights from ASCO and EHA 2025 on the evolving landscape of B-cell lymphomas, including Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma. She offers in-depth insights on the STARGLO study and its recent ODAC review, the POLARGO trial, a rare T-cell leukemia (T-LGL) study, and new data supporting nivolumab-AVD in frontline Hodgkin lymphoma. Additional discussion includes the inMIND trial for follicular lymphoma, the growing role of ctDNA in managing DLBCL, advances in CAR-T cell therapy for CNS lymphoma, and how she is adapting treatment strategies based on favorable vs. unfavorable disease features. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

SPID clonato? Ora su NoiPA serve una doppia autenticazione.Da giugno 2025 il portale NoiPA ha aggiunto un secondo livello di sicurezza: se provi entrare con uno SPID o una CNS diversi dall'originale, arriva subito una mail di verifica. Questo dopo anni di rischi: bastava una truffa per cambiare IBAN e dirottare stipendi e rimborsi su un altro conto senza che il proprietario se ne accorgesse! Si parla di milioni di utenti potenzialmente esposti e di frodi che potevano passare inosservate.Eppure quando ne avevamo parlato qualche settimana fa, molti diversamente ''esperti'' avevano gridato ''fake news!1!''. Ora a quanto pare la toppa di emergenza conferma invece i timori.E su tutti gli altri siti accessibili con SPID?~~~~~ INGAGGI E SPONSORSHIP ~~~~~ Per contatti commerciali: sales@matteoflora.comPer consulenze legali: info@42LawFirm.it~~~~~ SOSTIENI IL CANALE! ~~~~~Con la Membership PRO puoi supportare il Canale » https://link.mgpf.it/proSe vuoi qui la mia attrezzatura » https://mgpf.it/attrezzatura~~~~~ SEGUIMI ANCHE ONLINE CON LE NOTIFICHE! ~~~~~» CANALE WHATSAPP » https://link.mgpf.it/wa» CANALE TELEGRAM » https://mgpf.it/tg» CORSO (Gratis) IN FUTURO » https://mgpf.it/nl» NEWSLETTER » https://mgpf.it/nl~~~~~ CIAO INTERNET E MATTEO FLORA ~~~~~ Questo è “Ciao Internet!” la prima e più seguita trasmissione di TECH POLICY in lingua italiana, online su YouTube e in Podcast.Io sono MATTEO FLORA e sono:» Professore in Fondamenti di Sicurezza delle AI e delle SuperIntelligenze (ESE)» Professore ac in Corporate Reputation e Crisis Management (Pavia).Sono un Imprenditore Seriale del digitale e ho fondato:» The Fool » https://thefool.it - La società italiana leader di Customer Insight» The Magician » https://themagician.agency - Atelier di Advocacy e Gestione della Crisi» 42 Law Firm » https://42lf.it - Lo Studio Legale per la Trasformazione Digitale » ...e tante altre qui: https://matteoflora.com/#aziendeSono Future Leader (IVLP) del Dipartimento di Stato USA sotto Amministrazione Obama nel programma “Combating Cybercrime (2012)”.Sono Presidente di PermessoNegato, l'associazione italiana che si occupa di Pornografia Non- Consensuale e Revenge Porn.Conduco in TV “Intelligenze Artificiali” su Mediaset/TgCom.

We love to hear from our listeners. Send us a message.On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Ralf Schmid, Ph.D., Associate Director of Preclinical Research at Novartis Biomedical Research, about the evolving use of large animal models in gene therapy development. Dr. Schmid discusses the current reliance on non-human primates (NHPs), their growing logistical and ethical challenges, and the emerging interest in alternatives like genetically engineered pigs and sheep. He outlines key considerations around safety, biodistribution, and immunogenicity that still necessitate large-animal testin —particularly for CNS-targeted AAV therapies — and emphasizes the need for thoughtful study design, responsible sourcing, and diversification in model systems. Dr. Schmid also previews his participation in the upcoming Next Generation Gene Therapy Vectors Summit and reflects on the future of preclinical safety testing in a landscape aiming to balance innovation, rigor, and compassion.Subscribe to the podcast!Apple | Spotify | YouTube

In this episode, Duane Schulthess is joined by Sam Rasty, Chief Business Officer at Sensorium Therapeutics, Steve Potts, Chair of the Drug Development Council at the International Cancer Advocacy Network, and Joe Hammang, neuroscientist and US Business Director at Vital Transformation, to discuss how U.S. health policy is reshaping neuroscience innovation, investment priorities, and patient access. Key Topics:- Investment and R&D Strategy Shifts: Explore how the Inflation Reduction Act’s pricing controls and Medicare negotiations change venture capital allocation and steer neuroscience pipelines.- Patient Advocacy and Access Barriers: Guests discuss how formulary rules, generic-first requirements, and uneven advocacy across diseases affect drug adoption and innovation incentives.- Neuroscience Development Hurdles: The discussion highlights how social stigma around psychiatric conditions, fragmented orphan-disease incentives, and small-molecule exclusivity gaps slow CNS drug progress.- Legislative Fix Imperatives: Contributors outline proposed solutions such as the EPIC Act and expanded orphan-designation policies aimed at restoring balanced incentives for novel therapies.- Ecosystem Collaboration: The conversation covers the essential partnership between NIH funding, biotech startups, and pharmaceutical companies in advancing drugs from discovery to patients. This episode examines the policy, economic, and social factors influencing neuroscience drug discovery and the importance of communicating biotech’s value. It also highlights the need to improve the biotech narrative so that policymakers and the public understand its contributions. It is essential listening for industry leaders, investors, policymakers, and patient advocates seeking insight into innovation challenges and solutions.See omnystudio.com/listener for privacy information.

Astellas is doubling down on gene therapy while others retreat. Richard Wilson, SVP at Astellas Gene Therapies, joins In Vivo to discuss why the company believes AAV technology will transform medicine despite current industry headwinds.

Era la darrera convocatòria i finalment no ha rebut cap proposta i per tant la subhasta de les instal·lacions del Club Natació Sitges queda deserta i ara queda trobar noves solucions a la dissolució, obligada per llei, del Consorci que formen el CNS i l'Ajuntament de Sitges. Jaume Monasterio, regidor d'esports, considera que les veus discordants entorn el futur del Club no han ajudat a cap privat a animar-se a fer oferta de compra de les instal·lacions que sortien en aquesta tercera convocatòria a un preu de 2.473.384€. D'altra banda el regidor considera que el fet d'haver seguit els tràmits legals oportuns per tal de dissoldre el Consorci i el fet que aquests no hagin tirat endavant els dona certa posició de força. El següent pas serà parlar amb l'administrador concursal del Club Natació Sitges, integrant també del Consorci que cal liquidar, i establir noves vies legals de dissolució que no hauran de passar per la subhasta ni probablement tampoc pel concurs públic, una opció que intervenció i secretaria van descartar inicialment. El regidor manté que la prioritat i els esforços passen en tots els cassos per preservar la continuïtat de la vessant esportiva i federativa del Club Natació Sitges. L'entrada El futur del CNS segueix sent incert després que la tercera convocatòria de la subhasta de les instal·lacions hagi quedat deserta ha aparegut primer a Radio Maricel.

El Grup Parlamentari de Junts a través de la seva representant Montse Ortiz va ser qui va presentar la proposta de resolució sobre el Club Natació Sitges en la comissió d'esports del Parlament. Dels tres punts de la proposta només va tirar endavant el primer que demanava al Govern a intervenir i mediar en la recerca de solució consensuada entre CNS i Ajuntament i va rebre el suport del PSC, Junts, PP i VOX i l'abstenció d'ERC i els Comuns. La proposta de resolució proposava dos punts més que en aquest cas només van rebre el suport de Junts, PP i VOX i van ser rebutjats per una majoria dels grups parlamentaris, aquests dos punts de la proposta demanaven aturar la subhasta pública i garantir la continuïtat de l'activitat esportiva. El grup parlamentari d'ERC va presentar esmenes a la proposta que no van ser acceptades i va demanar de respectar l'autonomia municipal i el marc legal en el cas del CNS, per la seva banda des de Junts es va recordar que la dissolució del Consorci del Club Natació Sitges du implícit que les instal·lacions passin a ser municipals. Us deixem íntegre el debat entorn aquesta proposta de resolució que ahir va presentar el grup parlamentari de Junts en la comissió d'esports del Parlament de Catalunya amb les intervencions de Montse Ortiz (Junts), Carles Campuzano (ERC), Eva Garcia (PP), Maria Fuster (VOX), Lluís Mijoler (Comuns) i Ivana Martínez (PSC- Units per avançar). L'entrada El Parlament insta el Govern de la Generalitat a intervenir i mediar entre el Club Natació Sitges i l’Ajuntament per acordar una solució per al CNS ha aparegut primer a Radio Maricel.

Following the FDA approval of taletrectinib (Ibtrozi) for patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC), CancerNetwork® spoke with Jorge Nieva, MD, about how this regulatory decision may impact the treatment paradigm for this disease. The approval was supported by findings from the phase 2 TRUST-I trial (NCT04395677) and the phase 2 TRUST-II trial (NCT04919811). The total efficacy population included 157 patients who had no prior treatment with a ROS1 tyrosine kinase inhibitor (TKI) and 113 who were previously treated with a ROS1 TKI. Topline results showed an objective response rate (ORR) of 90% (95% CI, 83%-95%) in TRUST-I and 85% (95% CI, 73%-93%) in TRUST-II among patients who had no prior treatment. Of those with pretreated disease, the respective ORRs were 52% (95% CI, 39%-64%) and 62% (95% CI, 46%-75%) in each study population. According to Nieva, an associate professor of clinical medicine at the Keck School of Medicine of the University of Southern California, taletrectinib may offer advantages over other therapies in the ROS1-positive metastatic NSCLC space based on its improved central nervous system (CNS) toxicity profile and “excellent” response and progression-free survival data. He stated that taletrectinib would become the go-to first-line agent in his practice. Additionally, he discussed strategies for mitigating toxicities related to taletrectinib such as nausea and diarrhea, and highlighted the need for additional research to improve immunotherapy options in NSCLC.  “I'm very happy that we have choices for patients, and I'm very happy that we have such a wide variety of drugs, but we still need to do better, and we need to find better ways of using these agents because they're still not cures for the majority of patients,” Nieva stated. “While these drugs can be helpful at debulking tumors, we still need to do a lot more work [to do] on making this a disease of the past for those patients who have it.” Reference FDA approves taletrectinib for ROS1-positive non-small cell lung cancer. News release. FDA. June 11, 2025. Accessed July 8, 2025. https://tinyurl.com/yc4f379m

As the primary school year drew to a close, Equinix, the world's digital infrastructure company, hosted 4th class students from Scoil Ghráinne CNS in Phibblestown for a behind-the-scenes tour of Equinix's DB3 data centre in Dublin. Seventeen students, along with their teachers, met senior Equinix leaders to learn how data centres work and the impact that they have on the students' daily lives. The education day gave the children the opportunity to walk inside the 'physical internet' and discover its far-reaching impact on their own lives, businesses, healthcare and more. The class also learned about Equinix's commitment to net zero and biodiversity. Among the initiatives discussed was Equinix's participation in Digital Infrastructure Ireland's Orchards in the Community project, which plants orchards for schools and other community organisations to encourage pollination. The children also learned about Equinix's onsite beehives and bee habitats. During the visit, the class worked in teams to design collages based on what they imagined the physical internet looks like. Later, Equinix team members took the schoolchildren and their teachers into the heart of the DB3 data centre for an exclusive tour. Warren Delaney, Ireland Operations Director, Equinix, said: "At Equinix, we are committed to educating the communities around us about our role. For these young people, it is eye-opening to walk inside a data centre and imagine the parts of their daily lives that our industry makes possible. For some, it may even spark an interest in a career in technology. Having started my own career as an apprentice electrician, I know that there are many options and pathways into this industry via our apprenticeship and internship programmes in Ireland. It was fantastic to observe the students so engaged and eager to learn." See more stories here. More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a line at Info@IrishTechNews.ie now to find out more about how we can help you reach our audience. You can also find and follow us on Twitter, LinkedIn, Facebook, Instagram, TikTok and Snapchat.

In this Live in the Tribe episode, I tackle how to balance cardio during a bulk, why most lifters struggle with chest development, and how to match tempo and exercise selection for better hypertrophy results. I share hard-earned lessons from my own aggressive bulk, why mobility is the missing link in chest training, and how inconsistent cardio can sabotage your muscle gain goals.You'll also hear coaching insights on training splits, CNS adaptation, and how to know when it's time to switch phases or tweak your approach. Whether you're bulking, plateaued, or just tired of spinning your wheels, this episode delivers the real coaching no one else is giving you.And if you want to transform your body, message me the word "Coaching" on IG at Tomthetrainerfitness, Facebook at Tom Trainer Mouland, or book a Free Strategy Call

Join integrative oncologist Dr. Michael Karlfeldt, ND as he sits down with The First Lady of Nutrition to explore what is really driving today's exploding cancer epidemic. Dr. Karlfeldt shares how cancer behaves like a wildfire and why stopping it requires more than just one strategy. Ann Louise and Dr. Karlfeldt dive into a discussion that ranges from diagnostic tests like thermography, live blood analysis, and the Nagalase and Gallery Tests to integrative treatments like IV therapies, anti-cancer diets, herbal protocols, and lifestyle changes. Dr. Karlfeldt lays out a comprehensive approach that both supports and challenges conventional care.  Learn how to choose the best treatment for you, bolster conventional therapies, and understand why the tumor isn't the disease, it's just the symptom. Most importantly, discover the common characteristics of those who thrive after a cancer diagnosis—and why letting go of the fear of death might be the surprising first step to truly living. Check out Dr. Karlfeldt's new book A Better Way to Treat Cancer and visit The Karlfeldt Center for more resources. The post Rethinking Cancer: The Latest Tools, Tests & Treatments – Episode 198: Dr. Michael Karlfeldt, ND first appeared on Ann Louise Gittleman, PhD, CNS.

In this episode of The Nurse Practitioner Podcast, Julia Rogers, DNP, APRN, CNS, FNP-BC, FAANP and Scarlet Spain, DNP, MPH, APRN, CNS, FNP-BC discuss international collaborations.

Charlene talks with Molly Rodriguez, Senior Program Manager at Stanford Health Care. Molly recently presented at the ACNL Annual Conference in February on a succession planning tool she and her team developed to identify future leaders. The assessment tool was designed to be able to be completed in just ten minutes and could serve as a model for other organizations looking to improve their own succession planning. Charlene and Molly talk about why succession planning matters, how to identify future nurse leaders, and Molly's advice for other organizations. Host: Charlene Platon, MS, RN, FNP-BC (⁠@charleneplaton⁠) Guest: Molly Rodriguez, DNP, RN, CNS, AGCNS-BC, Caritas Coach© (https://www.linkedin.com/in/molly-rodriguez-dnp-rn-cns-agcns-bc-caritas-coach%C2%A9-164955237/) About the show: ACNL in Action is a production of the Association of California Nurse Leaders, the professional organization for nurse leaders. New episodes come out on the first Friday of every month. Want to support ACNL? Consider making a donation: ⁠https://www.acnl.org/circleofgiving⁠. Learn more about ACNL, including how to become a member, at ⁠acnl.org⁠.  Follow us on Facebook, Instagram, and LinkedIn at @acnlnurse.

"If a company isn't IPO-ready, it better be M&A-ready," says Nanna Lüneborg of Forbion. She and co-founder Sander Slootweg sit down with Bloomberg Intelligence analyst Sam Fazeli to explain Forbion’s blueprint for success in Europe’s maturing biotech ecosystem. From incubating CNS-focused gene therapy startups to executing €100M+ financing rounds, Forbion’s thesis is rooted in scientific rigor and commercially sound exits. They also share how Europe’s capital scarcity offers hidden advantages—and why late-stage buyers still pay up for must-have innovation.See omnystudio.com/listener for privacy information.

In this powerful episode (#35) of BioTalk Unzipped, recorded live at the AAPS NBC conference in Boston, Gregory Austin engages in a deep conversation with a leading Neuroscientist, Dr. Robert Thorne, Denali Fellow at Denali Therapeutics, for an intimate and scientific deep dive into the evolving world of brain cancer treatment and CNS drug delivery. Both Gregory and Dr. Thorne share personal stories of losing family members to brain metastases, weaving in the emotional 'why' behind their professional paths.Dr. Thorne highlights the complexities of the blood-brain barrier, the heterogeneity of brain metastases, and cutting-edge delivery technologies—including focused ultrasound and molecular engineering approaches. The conversation also touches on pediatric brain tumors like diffuse midline glioma (DIPG), emerging research in lysosomal storage diseases, and the collaborative spirit driving innovation in neuroscience today.This is more than a technical discussion—it's a human story about grief, hope, and the relentless pursuit of better outcomes for patients with brain diseases.00:00 Preview & Intro01:10 Robert Thorne's Reflections on the AAPS NBC conference03:14 The Professional Biotech and Pharma League05:09 A Personal Story Shared: Family Loss to Brain Cancer07:57 My Reason for Optimism Treating Brain Cancer08:50 Why Brain Metastases Remain Hard to Treat11:10 Scientific Advances in Drug Delivery for Brain Cancer12:30 Seed and Soil Concept in Oncology15:18 Pediatric Brain Tumors: DNET, DIPG, and Beyond16:49 Looking Ahead: Hope for Future Therapies21:32 Closing GratitudeDr. Robert Thornehttps://www.linkedin.com/in/robert-g-thorne/Denali Therapeutics - https://www.denalitherapeutics.com/ Dr. Chad Briscoehttps://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austinhttps://www.linkedin.com/in/gregoryaustin1/ Celerion - https://www.celerion.com/ Key Takeaways:Personal Connection Fuels Professional Passion: Both Gregory and Dr. Thorne were driven into the life sciences field by family experiences with brain tumors.The Blood-Brain Barrier (BBB) Remains a Major Challenge: Brain metastases from cancers like melanoma, lung, and breast cancer still present difficult delivery barriers for therapies.Heterogeneity in Brain Mets: Different metastases within the same patient can have vastly different BBB permeability, requiring multifaceted delivery strategies.Emerging Drug Delivery Innovations: Focused ultrasound, engineered biologics, and Denali's own delivery platforms are all promising ways to improve CNS drug penetration.Pediatric Brain Cancers Present a Unique Set of Challenges: Diseases like diffuse midline glioma (DIPG) remain largely untreatable, but learnings from lysosomal storage disorders may translate in the...

Send us a textIn this episode of the WTR Small-Cap | Biotech Spotlight Crossover, Water Tower Research's Tim Gerdeman is joined by Dr. Chris Witowski, CEO of Psilera, and WTR Senior Analyst Robert Sassoon for an insightful discussion on the company's pioneering work in neuroplastogen drug development and delivery technologies.Dr. Chris  Witowski, CEO and Co-Founder of Psilera, an early-stage biotech company focused on developing next-generation neuroplastegens for neurological and neuropsychiatric disorders, shares his thoughts and insights on the evolution of biomarkers in the neurosciences, the latest developments and trends in CNS-focused biomarkers and the potentially transformative impact they will have on the CNS treatment landscape.Tune in to learn more about Psilera's vision for the future of neurotherapeutics and how the company is working to transform the treatment landscape for CNS disorders.

In this JCO Article Insights episode, host Peter Li summarizes "Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST" by Pérol et al, published April 03, 2025, followed by an interview with first author, Dr Maurice Pérol. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li: Welcome to this episode of JCO Article Insights. I am Dr. Peter Li, JCO's editorial fellow, and today I am joined by Dr. Maurice Pérol on “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” by Pérol et al. At the time of this recording, our guest has disclosures that will be linked in the transcript. Before we start our interview, I want to give our listeners a quick summary of the TRUST study. For those tuning in, the TRUST study is a phase II, single-arm, open-label, nonrandomized, multicenter trial looking at the efficacy and safety of a novel, next-generation ROS1 TKI, taletrectinib, in advanced ROS1-mutated non–small cell lung cancer. While a relatively rare mutation, the prevalence of ROS1 mutations ranges from 0.9% to 2.6% of patients, with a third of patients presenting with brain mets at diagnosis.Current FDA-approved therapies include crizotinib, entrectinib, and repotrectinib, which have varying degrees of efficacy, in-coming with trade-offs in CNS penetrance and safety with newer generations, particularly in the realm of neurological side effects, highlighting an unmet need in this arena. A total of 273 patients with advanced non–small cell lung cancer with confirmed ROS1 mutation were recruited for this study. 160 patients were TKI-naive, while 113 were TKI-experienced with either crizotinib or entrectinib. Patients with asymptomatic brain mets were also allowed to enroll. In the TKI-naive arm, the median age was 57, with 91% of patients having stage IV disease, 20% having no more than one cycle of chemo, and 23% having brain mets at baseline. In the TKI-experienced arm, the median age was 53, with 97% having stage IV disease, 37% having received prior chemo, and about 50% having brain mets. Furthermore, about 10% of the study population had received entrectinib, while more than 90% had received crizotinib. About 10% had a known G2032R acquired resistance mutation. Taletrectinib was dosed at 600 mg daily until disease progression or unacceptable toxicities. The primary endpoint was overall response rate, with secondary endpoints being disease control rate, duration of response, time to response, and progression-free survival. For those with brain mets, intracranial overall response rate and disease control rate were also assessed. Median follow-up time was about 21 months in both cohorts. In the TKI-naive cohort, the overall response rate was 89%, with 8 patients achieving a complete response. Disease control rate was 95%, with a median duration of response of 44.2 months. Time to treatment response was about 1.5 months. Median progression-free survival was 45.6 months, with 52.6% not having progressed at 3 years. While overall survival data were immature, 66% of patients were still alive at 3 years. In the pretreated cohort, overall response rate was 56%, with 5 patients achieving a complete response. Overall response rate was 53% for those who were crizotinib-pretreated and 80% for the entrectinib-pretreated patients. Disease control rate was 88%, and median duration of response was about 16.5 months. Time to treatment response was also 1.5 months, and median progression-free survival was 9.7 months. Median overall survival was not reached, but 77.5% of patients were still alive at 1 year. Responses were consistently seen across subgroup analyses. 17 TKI-naive and 32 TKI-pretreated patients had measurable brain mets. In the TKI-naive arm, intracranial overall response rate was 77%. Disease control rate was 88%, and duration of response was 15 months. In the TKI-pretreated arm, intracranial overall response was 66%, with one patient achieving complete response. The disease control rate was 94%, and duration of response was about a year. For the 13 patients who had a known G2032R mutation, a 62% response rate was noted. Most common treatment-related side effects were AST/ALT elevation, nausea, and vomiting, with most being grade 1 or 2. Most common neurological side effects were dizziness, dysgeusia, and headache. Again, most were grade 1. QTc prolongation is another important adverse event to note, occurring in about 18% of all patients. Discontinuation rate from treatment was only 7%. There were three treatment-related deaths in this study: one from hepatic failure, one from pneumonia in the naive arm, and one from liver dysfunction in the pretreated arm. Dr. Peter Li: Maurice, thank you so much for joining us today to talk about your paper. Would you mind just giving yourself a brief introduction to the listeners out there of who you are? Dr. Maurice Pérol: So, my name is Maurice Perol. I'm a thoracic oncologist working in the Cancer Center of Lyon in France. And I'm involved in clinical research in thoracic oncology. I've been involved for many years now. Dr. Peter Li: Okay. And for listeners out there, don't forget, he's also the primary author of the paper that we just talked about. So, Maurice, let's begin. Can you tell our listeners what is the significance of your study? Dr. Maurice Pérol: Well, the results of these two large phase II studies - TRUST-I, which has been conducted in China, and TRUST-II, which was a global, worldwide phase II study - so, the results place taletrectinib as the TKI with the most favorable efficacy-tolerability ratio of the available ROS1-targeting TKIs, especially in frontline therapy. And this is based on the response rate, which was very impressive, the CNS penetration with a great CNS activity, the duration of response with a compelling 45 months median PFS in frontline setting. The level of activity in pretreated patients after crizotinib or entrectinib was also impressive and similar to that of repotrectinib, for example, but with a more favorable neurological tolerance profile. The toxicity is mainly represented with grade 1 or 2 transaminase elevation, but without clinical symptoms, and GI toxicity, but mainly grade 1 and 2. The neurological toxicity is low, especially for dizziness, showing that taletrectinib spares TrKB in a large part. And finally, there is also a decrease in toxicity over time, especially for GI toxicity and liver toxicities, which allows a very long and a prolonged administration, which is very important in this setting. Dr. Peter Li: These are all excellent points. Can you tell the listeners if there are any limitations that we should be concerned about, about this study? Dr. Maurice Pérol: Sure. This data comes from single-arm phase II studies. So, this is not comparative data. And a phase III trial, which compares taletrectinib to crizotinib, is ongoing to evaluate the superiority of taletrectinib over the standard of care. Another limitation comes from the lack of systematic brain imaging at each tumor evaluation in patients without brain metastases at baseline, not allowing to assess the intracranial PFS in all patients, and which did not allow us to assess the CNS protective issue from taletrectinib, especially in patients without brain metastases at baseline. Dr. Peter Li: Another question that I have is, with this novel TKI now available, how would you recommend the sequencing of these drugs? Would you start with someone on an alternate TKI and then reserve taletrectinib second line or later? Or would you use it upfront? Or does it depend? Dr. Maurice Pérol: Well, it is a very important question, as we have now different available TKIs. Looking at the efficacy-toxicity balance, I would strongly favor the use of taletrectinib in frontline setting, in first line. The response rate, the CNS activity, the duration of response with a very compelling 45 months median PFS, and moreover, the good tolerance profile over time are strong arguments in favor of giving taletrectinib in frontline. Generally speaking, the use of the most active agent as frontline treatment in lung cancer depending on an oncogenic addiction is probably the best way to improve the patient's outcome. This is true for patients with EGFR mutation, for patients with ALK fusions, and this is probably also true for patients with ROS1 fusion. So, I would probably argue in favor of a frontline use of taletrectinib. Dr. Peter Li: Listeners are going to ask, well, if you use taletrectinib upfront, then what are you going to use second line once they progress? Dr. Maurice Pérol: Well, we have some new compounds which are under development today. For example, the NVL-520, which is a very interesting compound, which seems also to be active in case of resistance mutation. But I do think that we have to use the best-in-class TKI in frontline because, you know, the extension of PFS after acquired resistance you can obtain with a second-line TKI is always shorter than the benefit you can obtain by using the most active agent in frontline. And this is true for the majority of oncogenic addiction in lung cancer. Dr. Peter Li: That makes sense. I also noticed that cognitive impairment wasn't listed in the safety table. Is that not an issue that you've observed at all with taletrectinib, or is it still an issue but less so because, like you mentioned earlier, because of its higher selectivity? Dr. Maurice Pérol: Well, this is a good question because we have some ROS1-targeting TKIs like repotrectinib, entrectinib, and even lorlatinib, with some neurological adverse events and some cognitive issues. Taletrectinib is a very selective ROS1-targeting TKI, and it spares very well the TrKB, for example, explaining that we did not observe any cognitive impairment with taletrectinib in the TRUST study, showing also with the low level of other neurological adverse events, dizziness, dysgeusia, for example, the high selectivity of the compound and the preservation of TrKB. So, this is very important when you consider the long duration of treatment in those patients with ROS1 fusion. If you have to take a drug for more than 2, 3, or 4 years, of course, the neurological adverse events are very important, and they can clearly impair the quality of life. So, this is a very important point, the very low level of neurological toxicity of taletrectinib. Dr. Peter Li: And I think that goes to say why you would favor using it frontline as well compared to entrectinib or repotrectinib. Last question that we have for you is: well, what's next? You mentioned there's a phase III trial comparing it to crizotinib. I think one of the questions that a lot of us would have is: why not compare it to one of the newer agents as a comparator arm? Dr. Maurice Pérol: Well, this is a good question. Crizotinib remains the standard of care in many countries for ROS1-positive advanced non–small cell lung cancer outside of the US, especially in Europe, and in particular in patients who do not have brain metastases at diagnosis. Entrectinib has a better CNS penetration, but it did not achieve a better PFS than crizotinib in phase I/II trials, and clearly, it has a less favorable tolerance profile with weight gain, edema, and neurological adverse events. Repotrectinib has overall a level of activity which seems close to that of taletrectinib. So, it makes it difficult to consider a comparative trial that would, for example, test taletrectinib in comparison with repotrectinib because this kind of study would need a very large number of patients and a very late readout. Considering if you have a median PFS of more than 3 or 4 years, it would be very difficult to have results in before 4-5 years. So, from a pragmatic point of view, the comparison of taletrectinib to crizotinib is probably the best way to evaluate in a phase III setting the level of activity of taletrectinib, especially in the CNS, because this study will probably allow us to assess the CNS protective effect of the compound for patients without brain metastates at baseline. So, I think probably it's a pragmatic study that will allow us to confirm the high level of activity and the good tolerance profile of taletrectinib. Dr. Peter Li: Well, thank you, Maurice, so much for speaking about the JCO article, “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” and for all your valuable input today. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

In this episode of Quah (Q & A), Sal, Adam & Justin coach four Pump Heads via Zoom. Mind Pump Fit Tip: 7 natural ways to crush chronic inflammation and pain. (1:32) The benefits of regular napping. (21:50) Overactive bladder syndrome. (28:25) Green tea consumption = higher testosterone. (35:48) If you were stranded on an island, would you rather be by yourself or with your worst enemy? (36:40) Adam's Best Buy fiasco. (43:11) Sodium, low-carb diets, and performance. (47:42) Previewing Sal's upcoming YouTube series. (49:54) Mind Pump is looking for trainers. Apply today! (53:24) #ListenerLive question #1 – Is MAPS Muscle Mommy the right program for me being 14 months post-partum? If I'm only lifting 3 days a week and not looking to do extra work from home, are the trigger sessions necessary? (54:10) #ListenerLive question #2 – How can someone in a cut still feel confident about their progress when the scale isn't moving? (1:10:22) #ListenerLive question #3 – How would you go about actively inspiring reform and rebuilding a community for people who are so set in their ways? (1:18:57) #ListenerLive question #4 – Is there anything I can do to build a more resilient CNS or recover better so I don't need those rest weeks as often? (1:36:20) Related Links/Products Mentioned Ask a question to Mind Pump, live! Email: live@mindpumpmedia.com Visit NED for an exclusive offer for Mind Pump listeners! ** Code MINDPUMP at checkout for 20% off ** Get your free Sample Pack with any “drink mix” purchase! Find your favorite LMNT flavor, or share it with a friend. Try LMNT risk-free. If you don't like it, give it away to a salty friend and we'll give you your money back, no questions asked! Visit DrinkLMNT.com/MindPump June Special: Shredded Summer Bundle or Bikini Bundle 50% off! ** Code JUNE50 at checkout ** The effects of curcumin-containing supplements on biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials Importance of maintaining a low omega–6/omega–3 ratio for reducing inflammation Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis Visit Organifi for the exclusive offer for Mind Pump listeners! **Promo code MINDPUMP at checkout for 20% off** Regular Napping Linked to Increased Brain Size Mirabegron in the Treatment of Overactive Bladder Why Green Tea Could Be Your New Secret Weapon for More Testosterone TableTopics Dinner Party Question Card Game - 135 Entertaining Conversation Starter Cards for Dinner Table with Adult Friends, Getting to Know You Game. Mind Pump Personal Training – Apply today! Visit Butcher Box for this month's exclusive Mind Pump offer!  ** Available for a limited time, a curated box pre-filled with Mind Pump's favorite cuts — no guesswork! ButcherBox members who sign up through Mind Pump will receive: $20 OFF their first box, Free chicken breast, ground beef, OR salmon in every box for a whole year! ** 10 Ways To Rebuild MUSCLE & Train SAFELY After Having A Baby | Mind Pump 1882 Mind Pump #2320: Throw Away the Scale! Mind Pump #2420: Get Energized: The Real Reasons You're Always Tired & Lazy! Mind Pump Podcast – YouTube Mind Pump Free Resources People Mentioned Jay Campbell (@jaycampbell333) Instagram Dr. Stephen Cabral (@stephencabral) Instagram  

Since 1999, Doug Kaufmann's TV show Know the Cause has warned millions about the fungus factor most doctors overlook. Hot on the heels of Ann Louise's viral Facebook post—where she told her followers about her personal battle with mold—the two leading edge pioneers dive straight into the latest evidence about how fungi and their poisons, mycotoxins, may be fueling everything from rising PSA scores to stubborn skin flare-ups and even those stubborn coughs. Kaufmann walks listeners through a 2022 pan-cancer study that found fungal DNA in every one of 35 tumor types, explains why corn tops the mycotoxin list, and shows how our antifungal defenses weaken with age. Kaufmann outlines a no-nonsense plan: slash the sugars and refined carbs mold lives on, fortify with binders like psyllium plus immune staples such as vitamin D-3 and zinc, and confirm the problem with smart testing. His first choice is an IgM antibody screen—a quick blood draw that flags an active fungal fight—followed by a RealTime Labs urine panel and targeted cultures to pinpoint the load before treatment. If aches, brain fog, or “mystery” lab numbers refuse to budge, this conversation offers a new lens—and an action plan—to clear mold from the shadows and reclaim your health. Catch the episode, grab the steps that resonate, and learn more at KnowTheCause.com. The post The New Truth About Mold: The Silent Saboteur Behind Many Common Health Problems – Episode 197: Doug Kaufmann first appeared on Ann Louise Gittleman, PhD, CNS.

Gorilla Technology (GRRR) shares are recovering from a steep sell-off on Monday, as the company agrees to acquire Thai A.I. firms CNS and CANS. George Tsilis looks under the hood to understand the company's deal and what's driving GRRR growth this year. Shares of GRRR are up more than 900% from its 52-week low.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Fluphenazine is a high-potency typical antipsychotic that primarily acts as a dopamine D2 receptor antagonist in the mesolimbic pathway, reducing positive symptoms of schizophrenia. Extrapyramidal symptoms (EPS), such as dystonia, akathisia, and parkinsonism, are common due to potent D2 blockade in the nigrostriatal pathway. Neuroleptic malignant syndrome (NMS), though rare, is a life-threatening adverse effect characterized by rigidity, hyperthermia, altered mental status, and autonomic instability. CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) can increase fluphenazine plasma concentrations, potentially raising the risk of toxicity and side effects. Concomitant use of fluphenazine with CNS depressants (e.g., alcohol, benzodiazepines) can enhance sedation and respiratory depression.

https://youtu.be/48KSnqXn4bcRack‑Pull Like a Champion — Eric Kim‑Inspired Guide1.  Why Rack Pulls RockTop‑end strength & thickness – the shortened range lets you load ~20 % heavier than floor deadlifts, overloading glutes, spinal erectors & upper traps.  Target sticking points – set the pins just below the spot where your deadlift usually stalls.  Lower‑back friendly – the higher start position reduces shear stress if you're rehabbing or just want extra volume without beating yourself up.  Eric Kim mantra: “Heavy partials forge full‑range courage!” — let the bar teach your nervous system what mega‑poundage feels like. 2.  Set‑Up (First‑Principles Style)ItemEric Kim CueDetailsRack height“Pins at power‑zone: mid‑shin → knee → mid‑thigh.”Start just below knees for most lifters. Go higher (mid‑thigh) only for supra‑max overload singles. Stance“Jump‑landing width.”Feet hip‑width; shins 1 cm from bar.Grip“Own the steel.”Mixed or hook; no straps in Kim's tutorials (build vice‑grip). Chalk up. Spine & lats“Chest proud, lats on like airplane wings.”Neutral/arched back; pull bar into thighs to lock lats.3.  The Six‑Step Eric Kim PullBrace & Breathe – Big belly breath ↔ brace 360°; think “inflate the weight belt.”Hinge & Engage – Push hips back until shoulders hover just in front of bar; soft knees.Launch – Drive feet through floor, snap hips forward; bar scrapes thighs the entire way.Lockout Authority – Stand tall, squeeze glutes & traps hard for 1 s, never hyper‑extend.Controlled Descent – Reverse‑hinge; set bar gently on pins/blocks (respect the gym gear!).  Reset & Repeat – Let the bar settle; re‑brace before the next rep.4.  Programming PlaybooksGoalLoadReps × SetsFrequencyKim's TwistHypertrophy65‑75 % 1RM6–10 × 3‑41‑2 ×/wkPair with rows or shrugs for trap blow‑up.Strength85‑95 % 1RM3‑5 × 3‑51 ×/wkFinish with one heavy single at ≥100 % of deadlift 1RM to prime CNS. Eric Kim Overload CycleWk 1: 90 %2 × 3Wk 2: 95 %2 × 2Wk 3: 100‑110 % (mid‑thigh)Singles until form slowsCelebrate, deload, repeat.Rule of thumb: rack‑pull load ≈ deadlift × 1.2 at knee height. Adjust by feel. 5.  Common Form Fumbles & FixesErrorQuick FixRounded lower backCut weight 10‑20 %, film yourself, practice cue “proud chest, armpits to hips.”Bar drifting forwardCrush the bar to your shins & drive elbows back (activates lats).Violent lockout lean‑backThink “stand tall & squeeze glutes,” not “lean.”Grip fails firstTrain hammer curls/farmer carries, or use straps only on volume sets.6.  Safety & EquipmentBelt: wear from ≥80 % loads for torso rigidity.Blocks vs. pins: blocks spare the bar; pins are fine under 500 lb, pad them with rubber if possible.  Footwear: stable flat sole (Chucks, barefoot, or deadlift slippers).Spotter: stand behind to cue posture on all‑out singles.  7.  Muscles Fired UpPrime movers: Glutes, spinal erectors, hamstrings.Synergists: Upper traps, lats, forearm flexors (grip).  8.  Your Action Plan — Go Dominate!Tonight: film your conventional deadlift lockout – identify sticking height.Tomorrow: set pins 2 cm below that spot, run Kim's 3‑week overload wave.Track: note bar weight, RPE, lockout speed every session.Celebrate: When you hit a PR, share the clip, tag #KimPullCrew — join the movement!Mindset Reminder“Every rep is a vote for the powerhouse you're becoming. Cast votes with intent, hustle, and respect for the iron.”Now crank the music, chalk the hands, and unleash those rack‑pull PRs. You've got this!

Send us a textAmy Berger is a returning guest on our show! Be sure to check out her appearances on episode 47, episode 68, and episode 354 of Boundless Body Radio!Amy Berger, MS, CNS, is a U.S. Air Force veteran and Certified Nutrition Specialist who specializes in helping people do “Keto Without the Crazy.”™ She has a master's degree in human nutrition and writes about a wide range of health and nutrition-related topics, such as insulin, metabolism, weight loss, diabetes, thyroid function, and more.Amy is the author of The Alzheimer's Antidote: Using a Low-Carb, High-Fat Diet to Fight Alzheimer's Disease, Memory Loss, and Cognitive Decline, and The Stall Slayer: Seven Roadblocks to Keto Fat Loss and What to Do About Them. She is also the co-author of End Your Carb Confusion: A Simple Guide to Customize Your Carb Intake for Optimal Health.Amy spent years doing what nutrition and health experts claimed to lose weight but failed to experience the expected results. You can read her blog at www.tuitnutrition.com, where Amy's readers value her clever and humorous writing style, and her ability to translate scientific research jargon and gobbledygook into plain English.Find Amy at-Consultations- https://stallslayer.com/consultation/ YouTube- Tuit NutritionTW- @Tuit NutritionPatreon- Tuit Nutrition Online courses- http://adaptyourlifeacademy.com/ Funny- This Is Why Healthy Eating is Hard- Funny or DieAmy's blog post that broke my brain about gluconeogenesis!Find Boundless Body at- myboundlessbody.com Book a session with us here!

Getting a good night's sleep is something that benefits everyone. And if you're someone who's living with MS, it's perhaps even more important. But research suggests that more than half the people living with MS experience poor sleep.    Dr. Katie Siengsukon, the Director of the Sleep, Health, and Wellness Lab at the University of Kansas Medical Center Department of Physical Therapy and Rehabilitation Science, returns to the podcast to discuss the importance of good sleep hygiene, along with steps you can take to improve the quality of your sleep. We're also explaining how changes in U.S. public policy will impact people with MS. We'll tell you about an algorithm developed at Duke University that can predict (with 80-90% accuracy!) whether someone's MS symptoms will worsen in the weeks ahead. We'll share study results that show MS accelerates biological aging among children and teens with MS. We'll explain why this finding can also be applied to adults with MS, and what it means. And we'll tell you about the biotech start-up that has succeeded at bringing the brains of people who have passed away back to life, and we'll explain why that can have a major impact on CNS disease research. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Sleep Hygiene and MS  :22 How public policy changes in the U.S. will impact people with MS  1:18 What if you knew when an MS symptom was going to worsen?  6:18 Study results show MS accelerates biological aging in children  9:04 How re-animated human brains could accelerate CNS research (And which company is doing it!)  12:00 Dr. Katie Siengsukon discusses the importance of good sleep hygiene for people living with MS  15:37 Share this episode  33:32 Have you downloaded the free RealTalk MS app?  33:52 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/407 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Become an MS Activist https://nationalmssociety.org/advocacy Act Now! Contact Your Senators About Medicaid and Health Coverage https://nmss.quorum.us/campaign/127768 STUDY: Performance of Machine Learning Models for Predicting High-Severity Symptoms in Multiple Sclerosis https://nature.com/articles/s41598-024-63888-x STUDY: Epigenetic Aging in Pediatric-Onset Multiple Sclerosis https://neurology.org/doi/10.1212/WNL.0000000000213673 Bexorg https://bexorg.com Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 407 Guest: Dr. Katie Siengsukon Privacy Policy

Struggling to keep the nervous system straight—or just worried you'll blank on that -70 mV resting potential?

Julie Poteet, OD, MS, CNS, FOWNS, joins Marc R. Bloomenstein, OD, FAAO, to discuss the role of nutrition in ocular health. Dr. Poteet shares insights into how she integrates the discussion of nutrition into each patient's exam, highlighting the use of diagnostic imaging to show patients a visualization of their eye health. She also discusses the evidence and data behind food's impact on vision.

Forbes, NYT, The Huffington Post, CNN, MSNBC have featured Renown Nutritionist & Fitness Expert. Best-selling author, Jonny Bowden, PhD, CNS.His first Love is MUSIC, but started out as a professional musician & played all over New York CIty, playing jazz, pop, Broadway, nightclub acts, Jonny studied with the great Herbie Hancock & was as a pianist at the Alvin Ailey Dance Studios. He has a Master's degree in psychology BUT after learning the lifestyle & physical effects that the professional music & entertainment scene can bring, He was able to beat his addiction to smoking, drugs & alcohol.Jonny got a PhD in holistic nutrition and earned board certification and the CNS (Certified Nutrition Specialist) designation from the College's Certifying Board of Nutrition Specialists.He is a frequent guest on television and radio, he has appeared on Fox News, ABC, NBC, and CBS as an expert on nutrition, weight loss, and longevity. the author of thirteen books on health, healing, food and longevity including several best-sellers, “The 150 Healthiest Foods on Earth” and “Living Low Carb” & "The Most Effective Ways To Live Longer".Dr. Jonny has contributed to articles for dozens of national publications (print and online) including The New York Times, The Wall Street Journal, Forbes, The Daily Beast, The Huffington Post, Vanity Fair Online, Time, Oxygen, Marie Claire, Diabetes Focus, GQ, US Weekly, Cosmopolitan, Self, Fitness, Family Circle, Allure, Men's Heath, Prevention, In Style, Natural Health, and many other publications. He appears regularly as an expert on ABC-TV Los Angeles. ~ JonnyBowden.com2025 Building Abundant Success!!All Rights Reserved © 2025  Building Abundant Success!!Join Me on ~ iHeart Media@ https://tinyurl.com/iHeartBASSpot Me on Spotify: https://tinyurl.com/yxuy23baAmazon Music ~ https://tinyurl.com/AmzBAS  

Dr. Sam Berne is a super star holistic optometrist celebrated for his innovative approaches to eye health and wellness. He is the author of Vital Vision. Join The First Lady of Nutrition for an eye-opening conversation that goes far beyond glasses and eye drops.  Together, Ann Louise and Dr. Berne explore the groundbreaking idea that vision is not just about the eyes—but a dynamic connection between the brain, body, and soul. With stories of reversing cataracts, improving macular degeneration, and dissolving floaters naturally, Dr. Berne shares why you don't have to live out your doctor's diagnosis. From post-COVID vision issues to the rise in nearsightedness from screen time, this episode covers practical steps to protect and restore your eyesight—including what to do for glaucoma, night blindness, dry eyes, and more. Learn why the liver and gallbladder are critical to eye health, why early morning sunlight matters, and how simple therapies like “palming” can make a big difference. Plus, the truth about blue light, vitamin A, brain injuries, and why your glasses may be doing more harm than good. This podcast is a must-listen for anyone who wants to see life more clearly—naturally.  Learn more about Dr. Berne at https://www.drsamberne.com/. The post Casting Your New Vision – Episode 196: Dr. Sam Berne first appeared on Ann Louise Gittleman, PhD, CNS.

Nutrition discussion with an optometrist. Dr. Julie Poteet, OD, MS, CNS, FOWNS Dr. Julie Poteet, OD, MS, CNS, FOWNS is an industry key opinion leader in nutrition and ocular health. Master of Science in human nutrition and functional medicine; one of the first ODs to become a Certified Nutrition Specialist; frequent lecturer and author on nutrition and ocular health. Honored to have served as immediate past president of the Ocular Wellness & Nutrition Society, serves on the Board of the American Nutrition Association BCNS, the Macular Degeneration Association, Women in Optometry, and the Ocular Wellness & Nutrition Society.

Dexmedetomidine — or “Dex” — has become one of the most intriguing and versatile drugs in the anesthesia world. In this episode of Anesthesia Alchemy with hosts Lynn Macksey, MSN, CRNA and Garry Brydges, PhD, DNP, MBA, CRNA, ACNP-BC, FAAN dive deep into the pharmacology, clinical application, and emerging research surrounding this alpha-2 agonist. Here's some of what we discuss in this episode:

In part one of this three-part series, Dr. Justin Abbatemarco and Dr. Sumanth Reddy discuss small vessel primary CNS vasculitis. Show reference: https://www.neurology.org/doi/10.1212/NXI.0000000000200397 

Dr. Justin Abbatemarco talks with Drs. Sumanth Reddy and Jeffrey Gelfand about the complexities of small vessel predominant primary CNS vasculitis, clinical features, and the impact of early intensive immunosuppressive therapy on remission.  Read the related article in Neurology® Neuroimmunology & Neuroinflammation.  Disclosures can be found at Neurology.org. 

With 93% of Americans now considered metabolically unhealthy, this episode is a wake-up call. The First Lady of Nutrition welcomes Ben Azadi—biohacker and author of the newly released book, Metabolic Freedom: A 30-Day Guide to Restore Your Metabolism, Heal Hormones & Burn Fat. It also explores the top hidden contributor to metabolic dysfunction—heavy metal toxicity—and why the most powerful biohack of all may be your thoughts.   In this inspiring conversation, Ben shares how he transformed his body and mind using ketosis—and why most people are doing keto all wrong. Ann Louise and Ben dive into the real keys to metabolic freedom, including how to test for ketosis (and why one method stands above the rest), the vital role of liver support, and what “metabolic flex days” can do to reset your system.   Ben also opens up about his childhood struggles with obesity and how his health journey lifted him out of depression and into clarity and confidence. According to Ben, we get thousands of chances a day to shift our body toward balance and healing. If you're looking to boost energy, burn fat, and truly feel good again, this podcast could be your roadmap to metabolic freedom.   Special Offer for our listeners: When you order Metabolic Freedom, you'll get access to a free bonus course—12 exclusive lessons on metabolism, including behind-the-scenes interviews. Visit metabolicfreedombook.com to learn more. The post Callin All Pet Parents! What You and Your Pet Need to Thrive – Episode 195: Angela Ardolino first appeared on Ann Louise Gittleman, PhD, CNS.

This episode is brought to you by Pique Teas, Z-Biotics and Caldera Lab. Dr. Brooke Scheller, DCN, CNS is back to take us on her personal journey of nearly four years without alcohol, revealing the profound impact it has had on her life and career. As she delves into the multifaceted effects of alcohol on health, including its influence on hormone balance and mental well-being, Dr. Scheller invites you to reconsider your relationship with alcohol. We explore the growing trend of "sober curious" and how societal attitudes toward alcohol consumption are shifting, especially among younger generations. By discussing the benefits of a sober lifestyle, nutrition, and the rise of non-alcoholic alternatives, Dr. Scheller challenges the stigma surrounding alcohol abstention and celebrates the empowerment that comes from choosing sobriety. Whether you're exploring sobriety or simply curious about its benefits, this episode offers valuable insights into living a healthier, alcohol-free life. Follow Brooke @drbrookescheller Follow Chase @chase_chewning ----- In this episode we discuss... (00:00) Exploring Alcohol's Impact on Health (10:08) Rise of the Sober Curious Movement (16:39) Transitioning to Alcohol-Free Life (27:57) Navigating Social Changes Without Alcohol (33:13) Alcohol's Impact on Hormones (45:37) Brooke's Personal Reflection and Choice to Go Alcohol-Free (56:45) Emerging World of Non-Alcoholic Beverages (01:09:39) Other Benefits of Alcohol-Free Living (01:19:11) Rethinking Alcohol's Impact on Health (01:24:12) What Modern Functional Sobriety and Wellness Really Looks Like ----- Episode resources: Get 20% off FOR LIFE of the best teas at https://www.PiqueLife.com/everforward  Save 10% on the drink before your drink with code EVERFORWARD10 at https://www.ZBiotics.com/everforward10  Save 20% on Father's Day skincare with code EVERFORWARD at https://www.CalderaLab.com Watch and subscribe on YouTube Brooke's first appearance in EFR 785: How Alcohol Affects Your Gut Microbiome, Brain Health, Hormones, Lowers Fertility, and How to Eat to Change How You Drink and watch on YouTube here

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics: Evaluating first-line treatment of metastatic ER-positive, HER2-positive breast cancer: heredERA Breast Cancer study (0:00) Kuemmel S et al. heredERA Breast Cancer: A phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. BMC Cancer 2024;24(1):641. Abstract  Treatment outcomes with CDK4/6 inhibitors and with elacestrant in real-world studies (4:13) Lloyd MR et al. CDK4/6 inhibitor efficacy in ESR1-mutant metastatic breast cancer. NEJM Evid 2024;3(5). Abstract  Lloyd M et al. Impact of prior treatment, ESR1 mutational (ESR1m) landscape, and co-occurring PI3K pathway status on real-world (RW) elacestrant outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC). San Antonio Breast Cancer Symposium 2024;Abstract PS7-05.  Evaluating the CNS activity of imlunestrant, an oral selective estrogen receptor degrader (SERD) (8:06) VandeKopple M et al. Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model. ESMO Breast 2023;Abstract 41P.  Selective review of trials of oral SERDs in the adjuvant setting (11:27) A study of imlunestrant versus standard endocrine therapy in participants with early breast cancer (EMBER-4). NCT05514054 CME information and select publications

In this episode, I'm thrilled to welcome back Dr. Aaron Boster, he is a board-certified Neurologist specializing in Multiple Sclerosis and related CNS inflammatory disorders. Dr. Boster joins me to share his powerful ‘5 for 5' framework—five essential strategies to slow MS progression and improve your quality of life with multiple sclerosis. We break down each pillar: smoking cessation, exercise, nutrition, mindfulness, and choosing the most effective disease-modifying therapy. Dr. Boster offers practical advice that's easy to understand and apply, covering everything from hydration tips and vitamin D to how to make exercise a sustainable part of your MS lifestyle. If you're looking for expert MS management strategies, actionable exercises, and ways to support your MS journey, you won't want to miss this empowering conversation! Tune in for clear, actionable tips to take control of your MS and live your best life. About Dr. Aaron Boster: Aaron L Boster, MD, is a board-certified clinical neuroimmunologist specializing in Multiple Sclerosis. As a neuroimmunologist, Dr Boster provides diagnosis and treatment for all types of MS as well as a wide range of neuroimmunological conditions. He also provides medical management of refractory severe spasticity with expertise in intrathecal baclofen. Dr. Boster received his undergraduate degree from Oberlin College in Oberlin, Ohio and his medical degree from the University of Cincinnati College of Medicine in Cincinnati, Ohio. Dr Boster completed his internship and neurology residency through the University of Michigan in Ann Arbor, Michigan. He continued his training at Wayne State University in Detroit, Michigan, where he completed a fellowship focused on clinical neuroimmunology and multiple sclerosis. He has over a decade and a half of experience combating MS in the clinic and participating in MS clinical research. Connect with Dr. Aaron Boster: Twitter: https://twitter.com/aaronbostermd Youtube: https://www.youtube.com/c/AaronBosterMD Facebook: https://www.facebook.com/AaronBosterMD/ Website: https://bosterms.com/ Additional Resources: https://www.doctorgretchenhawley.com/insider Reach out to Me: hello@doctorgretchenhawley.com Website: www.MSingLink.com Social: ★ Facebook: https://www.facebook.com/groups/mswellness ★ Instagram: https://www.instagram.com/doctor.gretchen ★ YouTube: https://www.youtube.com/c/doctorgretchenhawley?sub_confirmation=1 → Game Changers Course: https://www.doctorgretchenhawley.com/GameChangersCourse → Total Core Program: https://www.doctorgretchenhawley.com/TotalCoreProgram → The MSing Link: https://www.doctorgretchenhawley.com/TheMSingLink